Studies with interferon-alpha in human tumors.
Clinical trials with IFN-alpha, produced from buffy coats of leukocytes, have been going on at Radiumhemmet, Karolinska Hospital since 1969. In some of the benign and malignant tumor diseases studied, IFN has been shown to induce regressions. In the case of the benign tumor juvenile laryngeal papillomatosis, IFN has been shown to be superior to other treatment modalities. So far IFN has not been shown to be superior to conventional treatment in any of the malignant tumors studied.
D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D007822:Laryngeal Neoplasms / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D012516:Osteosarcoma / Q000628:therapy; D010051:Ovarian Neoplasms / Q000628:therapy; D010212:Papilloma / Q000628:therapy; D014571:Urologic Neoplasms / Q000628:therapy
D007370:Interferon Type I